<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697850</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1715</org_study_id>
    <secondary_id>2018-001807-35</secondary_id>
    <nct_id>NCT03697850</nct_id>
  </id_info>
  <brief_title>Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy</brief_title>
  <acronym>BladderSpar</acronym>
  <official_title>Phase II Study of Maintenance Anti-PD-L1 Treatment With Atezolizumab After Chemo-radiotherapy for Muscle-infiltrating Bladder Cancer Patients Not Eligible for Radical Cystectomy: Bladder Sparing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical
      cystectomy because of age, comorbidities, and/or patient's refusal.

      This study is designed as a multicentre, single-arm phase II study.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporary suspension since March 13 due to COVID-19 pandemic
  </why_stopped>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Disease Free Survival is defined as the delay between date of inclusion and tumour relapse (local, regional, or distant) or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>2 years</time_frame>
    <description>Local control rate will be evaluated by cystoscopy. The presence of non-muscle-invasive or muscle-invasive bladder cancers will be considered as a local failure. To be defined as locally controlled, the bladder must be completely free of tumour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>5 years</time_frame>
    <description>Local control rate will be evaluated by cystoscopy. The presence of non-muscle-invasive or muscle-invasive bladder cancers will be considered as a local failure. To be defined as locally controlled, the bladder must be completely free of tumour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease Free Survival is defined as the delay between date of inclusion and tumour relapse (local, regional, or distant) or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival is defined as the delay between the date of inclusion and the date of death, from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival is defined as the delay between the date of inclusion and the date of death, from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>The tolerance and safety will be evaluated by toxicity (acute [&lt;6 months after the start of atezolizumab] and late [≥6 months after the start of atezolizumab]), assessed using the NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>The tolerance and safety will be evaluated by toxicity (acute [&lt;6 months after the start of atezolizumab] and late [≥6 months after the start of atezolizumab]), assessed using the NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Core Questionnaire - Cancer Patients (QLQ-C30)</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Core Questionnaire - Bladder Cancer Muscle Invasive (QLQ-BLM30)</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Core Questionnaire - Elderly Cancer Patients (QLQ-ELD14)</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>G8 oncodage</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy</description>
    <arm_group_label>atezolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selection phase

        Inclusion Criteria:

          1. Muscle-invasive bladder cancer (MIBC) pT2-T3 histologically confirmed:

             Urothelial and squamous cell histological types are allowed. De novo MIBC or after a
             history of non-muscle-invasive bladder cancer.

          2. Complete transurethral resection of bladder tumour (TURBT), either:

             within 6 weeks of selection if no chemotherapy was administered, or before starting
             chemotherapy.

          3. Patients for which chemo-radiotherapy is planned

          4. No major pelvic involvement: pelvic nodes ≤15 mm on CT scan.

          5. No distant metastasis.

          6. Patient unfit for radical cystectomy because of age, comorbidities, or patient's
             refusal.

          7. Patients ≥18 years old

          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

          9. Life expectancy ≥12 months.

         10. Haematological and biological parameters:

             White blood cell count ≥4000/mm³ Platelet count ≥100000 cells/mm³ Haemoglobin level ≥9
             g/dL or corrected after transfusion A glomerular filtration rate ≥25 mL/min. Adequate
             renal function: clearance &gt;50 mL/min (MDRD). Adequate hepatic function: Aspartate
             aminotransferase (AST [SGOT]) and Alanine aminotransferase (ALT [SGPT]) ≤2.5 x upper
             limit of normal (ULN), or ≤3.5 x ULN in the case of concurrent disease with known
             etiology and for which a corrective treatment is possible.

         11. Patients of childbearing potential who agree to use a medically acceptable method of
             contraception during the study and for 120 days after the last study treatment. Women
             must have a negative urine or serum pregnancy test before receiving the study
             treatment and within 14 days prior to selection.

         12. Patients having provided written informed consent prior to any study-related
             procedures.

         13. Patients affiliated to the social security scheme.

         14. Patients willing and able to comply with the scheduled visits, treatment plan,
             laboratory tests, and other study procedures indicated in the protocol.

         15. Patient consents to the use of their collected tumour specimen, as well as, blood
             samples as detailed in the protocol for future scientific research which includes but
             not limited to DNA, RNA, and protein-based biomarker detection.

        Exclusion Criteria:

          1. Prior pelvic irradiation.

          2. MIBC histology other than urothelial or squamous cell carcinomas (e.g.,
             adenocarcinomas, micropapillary, sarcomas, or small cell histological types).

          3. History of neoplastic disease, during the 3 years before selection, except completely
             resected cutaneous basal-cell carcinomas, carcinoma in-situ or localised prostate
             cancer without biochemical recurrence following definitive treatment.

          4. Prior treatment with CD137 agonists or immune checkpoint inhibitors, including
             anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4), anti-programmed
             death-1 receptor (anti-PD-1), and anti-programmed death-ligand 1 (anti-PD-L1)
             therapeutic antibodies.

          5. Contraindications for pelvic radiotherapy (e.g., inflammatory bowel disease).

          6. History of immunodeficiency, including HIV infection, or systemic steroid therapy for
             any other disease.

          7. A history of active autoimmune disease, except autoimmune-related hypothyroidism and
             type I diabetes mellitus (see appendix 5).

          8. History of severe allergic anaphylactic reactions to chimeric, human or humanised
             antibodies, or fusion proteins.

          9. Known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component
             of the atezolizumab formulation.

         10. Prior allogeneic stem cell or solid organ transplant.

         11. Patients with the following severe acute co-morbidity are not eligible:

             Unstable angina or congestive heart failure that required hospitalisation in the 6
             months before selection.

             Transmural myocardial infarction in the 6 months prior to selection. Acute bacterial
             or fungal infection requiring intravenous antibiotics at selection.

             Chronic obstructive pulmonary disease exacerbation or other respiratory illness
             requiring hospitalisation or precluding study therapy at the time of selection.

             Severe hepatic disease: Child-Pugh Class B or C.

         12. Patients with any other disease or illness which requires hospitalisation or is
             incompatible with the study treatment are not eligible.

         13. Patients unable to comply with study obligations for geographic, social, or physical
             reasons, or who are unable to understand the purpose and procedures of the study.

         14. Patients enrolled in another therapeutic study within 30 days of selection.

         15. Pregnant or breast feeding women.

         16. Person deprived of their liberty or under protective custody or guardianship.

        Inclusion phase

        Inclusion Criteria:

          1. Patients who have received standard (chemo)-radiotherapy ≥60 gray (Gy) or equivalent
             on the bladder according to the local practice.

          2. The first administration of atezolizumab must be performed 30 (+/-5) days after the
             last session of radiotherapy (RT).

          3. ECOG performance status ≤2.

          4. Haematological and biological parameters:

             White blood cell count ≥4000/mm³ Platelet count ≥100000 cells/mm³ Haemoglobin level ≥9
             g/dL or corrected after transfusion A glomerular filtration rate ≥25 mL/min Adequate
             renal function: clearance &gt;50 mL/min (MDRD) Adequate hepatic function: AST (SGOT) and
             ALT (SGPT) ≤2.5 x ULN, or ≤3.5 x ULN in the case of concurrent disease with known
             etiology and for which a corrective treatment is possible.

          5. Patients of childbearing potential who agree to use a medically acceptable method of
             contraception during the study and for 120 days after the last study treatment. Women
             must have a negative urine or serum pregnancy test before receiving the study
             treatment and within 14 days prior to inclusion.

          6. Patients having provided written informed consent prior to any study-related
             procedures.

          7. Patients willing and able to comply with the scheduled visits, treatment plan,
             laboratory tests, and other study procedures indicated in the protocol.

          8. Patient consents to the use of their collected tumour specimen, as well as, blood
             samples as detailed in the protocol for future scientific research which includes but
             not limited to DNA, RNA, and protein-based biomarker detection.

        Exclusion Criteria:

        The same non-inclusion criteria of the selection phase have to be respected.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe HENNEQUIN, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icm Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Azureen de Cancerologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSTITUT de CANCEROLOGIE DE L'OUEST - site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

